Cancer Immunity, an open access, peer-reviewed journal published by the Cancer Research Institute, provides those interested in cancer immunology and immunotherapy an interactive vehicle for the dissemination of novel experimental discoveries and developments in the field.

We welcome papers that deal with all aspects of cancer immunology and immunotherapy, ranging from basic discoveries to late-stage clinical studies, from regulatory issues to statistical considerations in clinical trial designs. Rapid publication by leading tumor immunologists serves as a source of reference information not limited to:

cancer antigens and their diagnostic, prognostic, and clinical use
cancer immunosurveillance and immunoediting
the tumor microenvironment
biomarkers and immune correlates in clinical trials
solid or hematological malignancies
immunosuppressive and immunological escape mechanisms
cross-talk between innate and adaptive immune responses
inflammation and epigenetic control of inflammatory processes
vaccine- and antibody-based clinical trials
combined immunological and conventional anti-cancer therapies

Committed to reflecting the broad and growing influence of cancer immunology on the study of cancer and on the search for ways to control the disease, Cancer Immunity features four types of contributions:

Articles describing the results of original laboratory and clinical research.
Reviews providing critical and balanced views of specific topics.
Commentaries discussing papers recently published in Cancer Immunity or other journals. In addition, Cancer Immunity welcomes Commentaries dealing with any matter of importance to tumor immunology and immunotherapy.
Reflections presenting a personal perspective on the origins and history of the field of tumor immunology by leaders in the field. Reflections are invited by the editors.

For more information, visit www.cancerimmunity.org.

Publish with us.